Table 2 Association of HOXB13 p.R217C with breast cancer risk in women of European descent.

From: Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

 

N Controls

N Cases

CAF (%) Controls

CAF (%) Cases

OR (95% CI) *

P-value*

Overall analysis

Europeans

44,422

54,752

0.077

0.062

0.80 (0.48–1.32)

0.38

Subgroup analysis

Age of diagnosis

    < 50 years

44,422

17,669

0.077

0.045

0.38 (0.14–1.01)

0.05

Menopausal status

   Premenopausal

44,422

12,195

0.077

0.057

0.59 (0.24–1.44)

0.25

Family history

   1st degree relative with BC

41,909

7,531

0.069

0.013

0.21 (0.03–1.53)

0.12

Second BC

   Contralateral BC

38,346

2,137

0.076

0.047

0.43 (0.05–3.43)

0.43

Receptor status

   ER positive

44,422

35,930

0.077

0.061

0.81 (0.46–1.42)

0.46

   ER negative

44,422

9,343

0.077

0.064

0.82 (0.33–2.03)

0.66

   Triple negative

44,422

4,045

0.077

0.025

0.29 (0.04–2.19)

0.23

  1. N, number; CAF, carrier allele frequency; OR, odds ratio; CI, confidence interval; BC, breast cancer; ER, estrogen receptor.
  2. *Dominant genetic model adjusted for country, age and principal components. Not all BCAC studies had info on all variables.